New COVID-19 Therapy: Pemivibart

We have added the monoclonal antibody pemivibart to the COVID-19 Antiviral Therapies class of primary drugs.

Pemivibart was granted an Emergency Use Authorization by the FDA in March 2024, for use as pre-exposure prophylaxis in immunocompromised people who are unable to mount a sufficient response to COVID-19 vaccinations. Pemivibart is not hepatically metabolized or renally excreted, and so has minimal potential to cause drug-drug interactions.